Navigation Links
NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
Date:6/5/2011

ss release remain subject to audit and confirmation procedures, and therefore the results may change materially and adversely after such procedures are completed; (vi) the data in this press release is not necessarily predictive of the outcome of the expansion arm of the Phase 2 study of NKTR-102 in patients with platinum resistant/refractory ovarian that have received prior treatment with PLD—therefore the results from this expanded Phase 2 study population could be materially and adversely different than the results described in this press release; (vii) additional important data will be reported by Nektar in the future regarding the Phase 2 NKTR-102 clinical study in ovarian cancer (including without limitation the expansion arm of the study) and therefore the future results from this ongoing Phase 2 ovarian cancer study may differ materially and adversely from the preliminary interim results presented in this press release; (viii) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required in the future; (ix) the uncertain outcome of any future intellectual property, commercial or other litigation related to Nektar's proprietary product candidates, including without limitation NKTR-102; and (x) certain other important risks and uncertainties set forth in Nektar's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011, filed with the Securities and Exchange Commission on April 29, 2011.  Actual results could differ materially from the forward-looking statements contained in this press release.  Nektar undertakes no obligation to update forward-looking statements, including but not limited to any clinical, FDA or other regulatory information, whether as a result of new information, future events or otherwise.

Nektar Investor Inquiries:Jennifer Ruddock/Nekta
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
2. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
3. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
4. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
5. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
8. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
9. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
10. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
11. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)...  A substantial share of pharmacy and therapeutics ... are included in formularies—say patient support resources from ... Manhattan Research study, Taking the Pulse® Formulary ... P&T committee members in hospitals, managed care organizations ... a high bar for these programs, requiring that ...
(Date:7/31/2014)... FRANCISCO , July 31, 2014 ... and Aspira Scientific ( Milpitas, California ... venture to develop and commercialize new fluorination products ... active molecules has benefited from the use of ... and combine lipophilicity with polarity to improve binding ...
(Date:7/31/2014)... , July 31, 2014 For the ... can watch the implantation of the SynCardia temporary Total ... and matching video posted on the Journal of Visualized ... and read the paper on the SynCardia Total Artificial ... 16-minute video accompanies "Implantation of the SynCardia Total Artificial ...
Breaking Medicine Technology:Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 3
... N.J. and EDISON, N.J., June 8, 2011 ... they had entered into a broad-based collaboration agreement ... products. Under the terms of the agreement, AustarPharma ... manufacture products for Amerigen to commercialize in the ...
... Hospital ORs and ASCs (ambulatory surgery centers) face staffing ... to delegate non-care related tasks such as instrument purchasing ... Surgical, a 20+-year provider of high-quality specialty surgical ... an informed supply partner: Surgical instruments have ...
Cached Medicine Technology:Amerigen Pharmaceuticals and AustarPharma Enter Into Collaboration Agreement for Generic Oral Controlled Release Products 2Millennium Surgical's Smart Instrument Purchasing Saves OR Personnel Time, Money 2
(Date:8/1/2014)... 2014 Surftech athletes Jack Bark and ... World Championships this past weekend in Hawaii in commanding ... finisher Zeb Walsh were all on stock Surftech Bark ... race and athletes this year were treated to 6-10 ... course extremely challenging as well as very fast. ...
(Date:8/1/2014)... 01, 2014 iFitDress.com, a professional company ... new collection of 2014 silver bridesmaid dresses ... according to the latest fashion trends. What’s more, they ... 55 percent off. , iFitDress.com is one of ... in not only silver bridesmaid gowns, but also many ...
(Date:7/31/2014)... 2014) Women over the age of 65 face ... obesity, greater struggles against poverty and higher rates of ... the August issue of Annals of Allergy, Asthma ... College of Allergy, Asthma and Immunology (ACAAI), outlines the ... offers practical solutions to improve their care. ...
(Date:7/31/2014)... Developer Jamestown, L.P., has been using ... City Market project in Atlanta’s Old Fourth Ward, which ... building into best-in-class office, housing, and retail spaces. As ... with their construction webcam service to assess how it ... construction camera for monitoring and documentation purposes, ...
(Date:7/31/2014)... 31, 2014 In today’s world, a good ... get. Snoring and sleep apnea (a medical problem where the ... their bed partners of the rest they need to face ... population snores and 20 million people in the United States ... diagnosed and treated; and of those treated, many cannot tolerate ...
Breaking Medicine News(10 mins):Health News:Surftech Bark Commander Sweeps Molokai2Oahu Stock Paddleboard Division 2Health News:iFitDress.com: Beautiful Silver Bridesmaid Dresses at Promotional Prices 2Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... linked to iron deficiency, intravenous administration of iron increases ... says a Turkish study. ,Since oral iron replacement ... first choice for treatment for iron-deficiency anemia, Dr. Ragip ... it seems that intravenous iron sucrose is a safe ...
... 'small is good' and those small portions help us keep over ... pour 20-30% more alcohol // into short , wide glasses than ... believe that tall glasses hold more. The study finds mention ... public but seasoned and professional bartenders do the same mistake or ...
... of Jharkhand has given health the status of industry. ... to receive all facilities provided under the industrial policy. ... and infrastructure support. ,The government move is ... the health sector in state, where half the population ...
... Woods with other scientists from British Cardiac Society, ... the Primary Care Cardiovascular Society // and ... preventing cardiovascular risks of heart attacks, stroke and ... drafted to reduce the risk of developing heart ...
... of Medicine in St. Louis has found that survivors of ... as depressed as some studies make them out to be ... December issue of Supportive Care in Cancer. ,This study ... Center at Washington University School of Medicine and Barnes-Jewish Hospital. ...
... in the December 21 issue of the Journal of the ... radiation reduces the ability // to repair the chromosomal damage ... developing basal cell carcinoma and squamous cell carcinoma. ... is responsible for breaking DNA strands in exposed skin cells. ...
Cached Medicine News:Health News:Intravenous Iron treats anemia of pregnancy faster 2
... personal-sized Thermal Cycler is the ideal instrument for ... range of PCR applications. Get Applied ... Save lab space without sacrificing results. ... Industry-Standard PCR Technology You Can Afford ...
... Mastercycler ep Extremely fast heating and ... technology Intuitive graphic programming Can be ... system, or a PC-controlled network Heated lid ... Optional motorized lid for integration into fully ...
PTC-100 cycler with gold/silver block with Hot Bonnet heated lid, holds one 96-well V-plate or96x0.2ml tubes...
PxE thermal Cycler. 0.5ml block holds 48 0.5 ml tubes or 96 0.3 ml tubes. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User frien...
Medicine Products: